ABSTRACT. The accuracy of prenatal diagnosis for abnormal chromosome diseases by chromosome microarray technology and karyotyping were compared. A literature search was carried out in the MEDLINE database with the keywords "chromosome" and "karyotype" and "genetic testing" and "prenatal diagnosis" and "oligonucleotide array sequence". The studies obtained were filtered by using the QUADAS tool, and studies conforming to the quality standard were fully analyzed. There was one paper conforming to the QUADAS standards including 4406 gravidas with adaptability syndromes of prenatal diagnosis including elderly parturient women, abnormal structure by type-B ultrasound, and other abnormalities. Microarray technology yielded successful diagnoses in 4340 cases (98.8%), and there was no need for tissue culture in 87.9% of the samples. All aneuploids and non-parallel translocations in 4282 cases of non-chimera identified by karyotyping could be detected using microarray analysis technology, whereas parallel translocations and fetal triploids could not be detected by microarray analysis technology. In the samples with normal karyotyping results, type-B ultrasound showed that 6% of chromosomal deficiencies or chromosome duplications could be detected by microarray technology, and the same abnormal chromosomes were detected in 1.7% of elderly parturient women and samples with positive serology screening results. In the prenatal diagnosis test, compared with karyotyping, microarray technology could identify the extra cell genetic information with clinical significance, aneuploids, and non-parallel translocations; however, its disadvantage is that it could not identify parallel translocations and triploids.
INTRODUCTION
As chromosome microarray analysis technology has developed, it has gradually become an important instrument for diagnosing abnormal chromosome structure and child hypoevolutism (Geifman-Holtzman and Ober, 2008) . The aim of this study was to evaluate the accuracy and effect of microarray technology for routine prenatal diagnosis and additional fields relative to karyotyping. In this study, the accuracy, effect, and advantages of microarray technology compared to karyotyping were systematically evaluated by analyzing the relevant literature conducting comparative analysis on the two prenatal diagnosis techniques so as to provide medical evidence-based data for clinical research and large-scale applications in the near future.
MATERIAL AND METHODS

Searching strategy
The literature search was conducted in the MEDLINE database with the time period set from 1997 to 2013 using the following key words: chromosome and karyotype and genetic testing and prenatal diagnosis and oligonucleotide array sequence. The language was set to English and Chinese.
Selection criteria
The following criteria were used to select the literature included in the present analysis: 1) the research objective was to determine the accuracy and feasibility of microarray technology for prenatal diagnosis; 2) the accuracy determining process was compared to the traditional golden standard of karyotyping.
Literature selection
Two groups of independent experts judged the literature suitability based on the selection criteria by reading titles and abstracts. Studies consistent with the criteria were directly selected for this study, while those inconsistent were further evaluated by reading the full paper. In cases where the same data was published several times, only the most recent publication was selected for this analysis.
Data collection
All studies selected for inclusion in the analysis must have included an accuracy analysis on non-invasive diagnosis and a simultaneous comparison analysis of the traditional karyotyping method. The sensitivity and specificity, along with 95% confidence intervals, of the non-invasive method were estimated from all data obtained from the literature selected.
RESULTS
Literature selection
The literature selection process is shown in Figure 1 . There were 118 studies obtained from the key word search. After screening titles and abstracts, 8 studies related to microarray prenatal diagnosis were obtained and selected for further screening by reading the full text (Lim et al., 2010; Chiu et al., 2010; Papoulidis et al., 2012; Stumm et al., 2012; Talkowski et al., 2012; Schmid et al., 2013; Simpson, 2013; Vaiopoulos et al., 2013) . Among these, 2 studies were disease case reports and 5 investigated microarray techniques for different fields but did not judge noninvasive prenatal accuracy at a large scale; therefore, these studies were excluded. One study was excluded since it did not include a control for the golden standard (Table 1) . Finally, the one remaining study was selected for this analysis. 
Data analysis
As shown in Table 2 , microarray analysis could detect abnormal heterosome, trisomy 21, trisomy 18, and trisomy 13 as well as other chromosome abnormalities and non-parallel translocations detected by karyotyping, but only karyotyping, and not microarray, could detect triploidy and parallel translocations.
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DISCUSSION
In this study, the microarray effect on common prenatal diagnosis for aneuploidy was found to be equivalent to the current standard of chromosome karyotyping. In 1.7% of cases with prenatal diagnosis syndrome (elderly parturient women and positive aneuploid screening results), microarray provided additional relevant clinical information. In 6.0% of cases with abnormal type-B ultrasound results, microarray provided relevant clinical information. These results indicated that microarray is an advantageous test standard for prenatal screening; however, microarray and chromosome karyotyping analysis can detect uncertain mutations with clinical significance, which brings about challenges for genetic consultation and induces anxiety (Qu et al., 2013) .
A microarray design was used in the study analyzed herein to detect characteristic micro-deficiencies and duplications to a maximum degree, and also contained oligonucleotide regions distributed in the genome to detect additional chromosomal imbalances. Of all normal cases analyzed by karyotyping, 3.4% (130/3822) were further analyzed by microarray owing to uncertain results. Of these 130 cases, confirmed diagnoses were difficult in 94 (72.3%) cases. Thus, expert reviews for clinical correlations are necessary.
The results obtained from uncultured samples were selected a priori in this study in order to avoid additional time and instruments for cell and tissue culturing. However, based on traditional genetic analysis and placental chimera experiments limited to chorion samples, different results will be obtained by evaluating direct samples of cytotrophoblasts (non-cultured) and classically cultured samples originating from the villous stroma core. Microarray analysis on non-cultured samples overcomes the genome contents of these 2 cell lines. Although the preliminary data showed that the microarray analysis results appear to be reliable between paired cultured cells and non-cultured cells, further evaluations are necessary due to the limited sample size.
After about 12 weeks of pregnancy, abnormal triploid cases are apparent by ultrasound, which leads to further evaluation by chromosome karyotyping; however, these abnormalities may not appear in pregnancies less than 12 weeks along. Microarray analysis includes single nucleotide polymorphism (SNP) probes to identify triploids with genotype data (Liu et al., 2012) , but this information was not included in the research design.
Genotype data of SNP probes from the Affymetrix Company were not used in the microarray analysis investigated here, since this study was published before clinical applications of SNP probes became standard practice. However, since this study was published, it was confirmed that triploids could be identified by SNP data analysis. Therefore, we suggest that prenatal examinations should include SNP probe data analysis for more reliable triploid testing.
It is important to evaluate the incremental information degree required for effective prenatal examinations, and how to best introduce such information to clinical settings. We here found that microarray could detect abnormal heterosomes, trisomy 21, trisomy 18, and trisomy 13, as well as other chromosome abnormalities and non-parallel translocations that were detected by karyotyping, but only karyotyping could detect triploidy and parallel translocations, Microarray could improve the identification rate for detecting chromosome microdeficiencies and micro-amplification, decrease the omission rate caused by an insufficient identification rate of karyotyping, and explain more clinical features at the chromosome level.
When maternal blood samples are used for fetal genome sequencing, microarray analysis may be beneficial. Once this technology becomes clinically available, its application should be successful.
